Does Rallies show Form 4 insider transactions for ACHV?

Yes. Rallies tracks ACHV insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ACHV research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ACHV. It does not provide personalized investment advice.

ACHV (Achieve Life Sciences, Inc.) Stock Analysis - Insider Trades

Achieve Life Sciences, Inc. (ACHV) is a publicly traded Healthcare sector company. As of May 19, 2026, ACHV trades at $4.50 with a market cap of $489.68M and a P/E ratio of -3.61. ACHV moved -6.60% today. Year to date, ACHV is -10.46%; over the trailing twelve months it is +34.44%. Its 52-week range spans $1.84 to $6.15. Analyst consensus is strong buy with an average price target of $13.20. Rallies surfaces ACHV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ACHV stock inside the company?

Recent ACHV insider activity includes Oki Mark K sold 50.06K, Stewart Richard Alistair sold 129.50K, Wan Jerry sold 14.07K, KING THOMAS BRAXTON sold 139.86K, and JACOBS CINDY sold 27.63K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ACHV Key Metrics

Key financial metrics for ACHV
Metric	Value
Price	$4.50
Market Cap	$489.68M
P/E Ratio	-3.61
EPS	$-1.25
Dividend Yield	0.00%
52-Week High	$6.15
52-Week Low	$1.84
Volume	1.28M
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-54.65M
Gross Margin	0.00%

Recent ACHV Insider Trades

Oki Mark K sold 50.06K (~$146.18K) on Sep 18, 2025.
Stewart Richard Alistair sold 129.50K (~$378.14K) on Sep 18, 2025.
Wan Jerry sold 14.07K (~$38.97K) on Sep 4, 2025.
KING THOMAS BRAXTON sold 139.86K (~$387.41K) on Sep 4, 2025.
JACOBS CINDY sold 27.63K (~$76.53K) on Sep 4, 2025.

Latest ACHV News

Achieve Life Sciences Shows 2.5% Nausea Rate in 52-Week Cytisinicline Safety Trial — May 19, 2026
Achieve Life Sciences Raises $354M, Names New CEO, Partners with Adare — May 12, 2026
Achieve Life Sciences Raises $354M in Private Placement, Appoints New CEO — Apr 16, 2026
Achieve Completes Analytical Transfer and First Engineering Batch for Cytisinicline at Adare’s Ohio Facility — Apr 15, 2026
Achieve Life Sciences Secures US Manufacturing for Cytisinicline Ahead of June 23 PDUFA — Mar 24, 2026

ACHV Analyst Consensus

5 analysts cover ACHV: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $13.20.

Common questions about ACHV

Who is trading ACHV stock inside the company?: Recent ACHV insider activity includes Oki Mark K sold 50.06K, Stewart Richard Alistair sold 129.50K, Wan Jerry sold 14.07K, KING THOMAS BRAXTON sold 139.86K, and JACOBS CINDY sold 27.63K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ACHV?: Yes. Rallies tracks ACHV insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ACHV research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ACHV. It does not provide personalized investment advice.